Fly News Breaks for March 10, 2015
BAX, CTIC, INCY
Mar 10, 2015 | 08:07 EDT
After CTI BioPharma (CTIC) and Baxter (BAX) reported positive data for its JAK2/FLT3 inhibitor, pacritinib, which competes with Incyte's (INCY) Jakafi, JMP Securities does not expect pacritinib to gain much share, as the firm thinks it has "a cumbersome safety profile." JMP Securities reiterates a $97 price target and Outperform rating on Incyte.
News For INCY;CTIC;BAX From the Last 2 Days
There are no results for your query INCY;CTIC;BAX